Drug news
Picato(Leo Pharma) fails IQWiG assessment for Actinic Keratosis in Germany
In a preliminary assessment, the German Institute for Quality and Efficiency in Health Care ( IQWiG) has concluded that Leo Pharma's Picato gel (ingenol mebutate) for Actinic Keratosis, does not provide any added benefit over diclofenac/hyaluronic.
IQWiG commented that the drug manufacturer did not submit any relevant data: it did not cite any studies that directly compared ingenol mebutate with diclofenac/hyaluronic acid gel, and the method chosen by the manufacturer for an indirect comparison was unsuitable.